ArticleNature2022
The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
7.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Genetic landscape and functional exploration of kidney cancer predisposition in cross-ancestral populations.Nature communications · 2026Pooled it
- Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.Nature genetics · 2024Pooled it
- GADD45A may be a potential biomarker associated with endoplasmic reticulum stress in focal segmental glomerulosclerosis.Biochemistry and biophysics reports · 2026Article
- SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer.Nature communications · 2026Article
- Article
- Perturbation of BRD4 and p300 activity suppresses super enhancer‑drivenOncology reports · 2026Article
- Glucocorticoids elevate clear cell renal cell carcinoma sensitivity to HIF-2α inhibitors by suppressing H4K12 lactylation.Signal transduction and targeted therapy · 2026Article
- JAK2V617F reprograms Hypoxia Inducible Factor-1 to induce a non-canonical hypoxia regulon in myeloproliferative neoplasms.Leukemia · 2026Article
- Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritability.Cell reports · 2026Article
- HIF sustain a transcriptional regulatory circuit of EPAS1 expression in renal clear cell carcinoma.Nature communications · 2026Article
- Combining spatial and single-cell transcriptome data to analyze tertiary lymphoid structures in clear cell renal cell carcinoma reveals prognostic biomarkers.Journal of translational medicine · 2026Article
- Divergent cytotoxic and inflammatory functions of intratumoral Vδ2Frontiers in immunology · 2026Article
- RSK4 promotes the metastasis of clear cell renal cell carcinoma by activating RUNX1-mediated angiogenesis.Cancer biology & therapy · 2025Article
- TBCancer: A database for exploring characteristics and functions of tissue-biased genes in cancer.iMetaOmics · 2025Article
- Deciphering genetic susceptibility to clear cell renal cell carcinoma.Communications biology · 2025Article
- Integrative multi-omic analysis identifies key transcription factors and target proteins in renal cell carcinoma and its subtypes.bioRxiv : the preprint server for biology · 2025Article
- Circulating chromatin reveals the effects of disease-associated variants on gene regulation.bioRxiv : the preprint server for biology · 2025Article
- Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.British journal of cancer · 2025Article
- HIFα isoform specific activities drive cell-type specificity of VHL-associated oncogenesis.Nature communications · 2025Article
- SFPQ-TFE3 reciprocally regulates mTORC1 and induces lineage plasticity in a mouse model of renal tumorigenesis.Nature communications · 2025Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
27 authors at 6 institutions in 5 countries.
Saroor A PatelMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Shoko HirosueMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.ORCID http://orcid.org/0000-0003-1287-471X
Paulo RodriguesMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Erika VojtasovaMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.ORCID http://orcid.org/0000-0001-9255-8551
Emma K RichardsonMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Jianfeng GeMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Saiful E SyafruddinMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Alyson SpeedMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Evangelia K PapachristouCancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, UK.ORCID http://orcid.org/0000-0002-5835-2055
David BakerQuadram Institute Bioscience, Norwich Research Park, Norwich, UK.
David ClarkeCambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Stephenie PurvisCambridge Genomics Laboratory, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Ludovic WesolowskiMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Anna DyasMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Leticia CastillonMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Veronica CaraffiniMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Dóra BiharyMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.
Cissy YongDepartment of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
David J HarrisonSchool of Medicine, University of St Andrews, St Andrews, UK.ORCID http://orcid.org/0000-0001-9041-9988
Grant D StewartDepartment of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.ORCID http://orcid.org/0000-0003-3188-9140
Mitchell J MachielaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.ORCID http://orcid.org/0000-0001-6538-9705
Mark P PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.ORCID http://orcid.org/0000-0002-2324-3393
Anne Y WarrenDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID http://orcid.org/0000-0002-1170-7867
Shamith A SamarajiwaMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK.ORCID http://orcid.org/0000-0003-1046-0601
Jason S CarrollCancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, UK.ORCID http://orcid.org/0000-0003-3643-0080
Sakari VanharantaMRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge Biomedical Campus, Cambridge, UK. sakari.vanharanta@helsinki.fi.ORCID http://orcid.org/0000-0001-5619-7963
University of Cambridge · GBCambridge University Hospitals NHS Foundation Trust · GBNational Cancer Institute · USUniversity of Helsinki · FINorwich Research Park · GBUniversity of St Andrews · GB
Funding
Medical Research Council MC_UP_1101/4Medical Research Council MC_UU_12022/10Medical Research Council MC_UU_12022/7
Abstract
Large-scale human genetic data
Indexed as
CarcinogenesisKidney NeoplasmsPAX8 Transcription FactorSignal TransductionAllelesBasic Helix-Loop-Helix ProteinsCarcinoma, Renal CellCyclin D1Endothelial PAS Domain-Containing Protein 1Gene Expression Regulation, NeoplasticHumansKidneyMutationProto-Oncogene Proteins c-mycVon Hippel-Lindau Tumor Suppressor ProteinBasic Helix-Loop-Helix ProteinsCCND1 protein, humanCyclin D1Endothelial PAS Domain-Containing Protein 1MYC protein, humanPAX8 protein, humanPAX8 Transcription FactorProto-Oncogene Proteins c-mycVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.